News
BDTX
1.860
+15.53%
0.250
Weekly Report: what happened at BDTX last week (0615-0619)?
Weekly Report · 3d ago
Weekly Report: what happened at BDTX last week (0608-0612)?
Weekly Report · 06/15 09:31
Weekly Report: what happened at BDTX last week (0601-0605)?
Weekly Report · 06/08 09:29
Black Diamond Therapeutics Touts Silevertinib Lung Cancer Data, Eyes FDA Path
Barchart · 06/06 04:04
Wedbush Remains a Buy on Black Diamond Therapeutics (BDTX)
TipRanks · 06/01 13:35
Weekly Report: what happened at BDTX last week (0525-0529)?
Weekly Report · 06/01 09:31
BDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh Catalyst
NASDAQ · 05/27 15:16
Black Diamond Stock Outlook After Q1 Beat and Cash Runway
NASDAQ · 05/27 15:13
BDTX Silevertinib Data in EGFR NSCLC: What Investors Need to Know
NASDAQ · 05/27 15:10
What's Going On With Black Diamond Therapeutics Stock Tuesday?
Benzinga · 05/26 15:31
BDTX Stock Slumps on Mixed Phase II Frontline NSCLC Study Data
NASDAQ · 05/25 14:53
Weekly Report: what happened at BDTX last week (0518-0522)?
Weekly Report · 05/25 09:32
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 05/22 17:05
Black Diamond Therapeutics CEO joins Jefferies Global Healthcare Conference fireside chat
PUBT · 05/22 12:02
Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (ARWR), Black Diamond Therapeutics (BDTX) and Iovance Biotherapeutics (IOVA)
TipRanks · 05/22 10:30
Black Diamond Plunges Despite Positive Phase 2 Results For Silevertinib In 1L NSCLC
NASDAQ · 05/22 08:10
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
Barchart · 05/22 07:00
Black Diamond Highlights Positive Phase 2 Silevertinib Lung Cancer Data
TipRanks · 05/22 00:20
Black Diamond Therapeutics' Silevertinib Shows 15.2-Month Median PFS And 60% Response Rate With CNS Activity In EGFR Non-Classical Mutation NSCLC Phase 2 Study
Benzinga · 05/21 21:15
Black Diamond reports Phase 2 silevertinib mPFS 15.2 months in frontline EGFR-mutant NSCLC
PUBT · 05/21 21:14
More
Webull provides a variety of real-time BDTX stock news. You can receive the latest news about Black Diamond Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About BDTX
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.